Public health opportunities resulting from sufficient HPV vaccine supply and a single-dose vaccination schedule. (4th October 2022)

• Record Type: Journal Article
• Authors: Kreimer, Aimée R; Cernuschi, Tania; Rees, Helen; Brotherton, Julia M L; Porras, Carolina; Schiller, John
• Is Part Of: Journal of the National Cancer Institute. Volume 115:Number 3(2023)
• Page Start: 246
• Page End: 249
• Publication Date: 2022-10-04
• Subjects: Cancer -- Periodicals; Cancer -- Research -- Periodicals; 616.994
• DOI: 10.1093/jnci/djac189
• Languages: English
• ISSNs: 0027-8874

Abstract

Abstract: Many countries with the highest burdens of cervical cancer have not yet offered human papillomavirus (HPV) vaccines to most of their age-eligible girls, who as adults also have limited or no access to effective cervical cancer screening or treatment. There are now 2 complementary developments that could make HPV vaccines more accessible and affordable: 1) the current and projected increases in HPV vaccine supply; and 2) the permissive recommendation for single-dose HPV vaccination schedules. This change in policy paired with the healthier HPV vaccine supply is an incredible opportunity to facilitate rapid access and expansion of HPV vaccination. Female adolescent vaccination including multiage cohorts must be prioritized. In the coming decades, this is the most cost-effective approach to avert millions of projected cervical cancer cases, which account for most HPV-related cancers globally.